March 1, 2021
Business News

TrialScope Supports Moderna for Diversity Enrollment in Moderna’s Phase 3 Study of its COVID-19 Vaccine


JERSEY CITY, N.J.–()–Fulfilling a commitment to diversity and inclusion in the Phase 3 COVE Study of the Moderna COVID-19 Vaccine, Moderna enlisted the help of TrialScope, the global leader in clinical trial disclosure and transparency technology, for patient recruitment. Moderna utilized TrialScope Connect, an industry-first patient referral collective that connects sponsors and clinical trial recruitment partners to rapidly find, screen and enroll clinical trial participants.

In October 2020, Moderna completed recruitment of more than 30,000 participants in the Phase 3 study of its COVID-19 Vaccine, utilizing TrialScope Connect’s platform in the final enrollment period to ensure inclusion of participants…



Click here to view the original article.

Related Posts

You might also like ...

Accenture Acquires Leadership and Talent Consultancy Cirrus to Support C-Suite Transformations
Crescent European Specialty Lending Announces Unitranche Financing for Frontier Medical
Chevron Invests in Geothermal Development Company